T H 17 cells and the IL-17 family of cytokines are key drivers of autoimmune diseases, such as psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis (AS), rheumatoid arthritis (RA), and multiple sclerosis (MS). 1 Psoriasis is the best studied of these diseases, with multiple interventions targeted at T H 17 cells and their cytokines showing efficacy in its treatment.
The IL-17 family of cytokines includes 6 members (IL-17A to IL-17F) that function as homodimers or heterodimers to signal through a family of cytokine receptors with multiple chains (IL-17RA to IL-17RE), with IL-17A and IL-17F signaling through a receptor complex composed of IL-17RA and IL-17RC. 2, 3 Circulating levels of IL-17A protein have been shown to be higher in patients with psoriasis than in healthy control subjects and correlate with disease severity, 4 whereas mRNA expression of the IL17A, IL17C, and IL17F genes is higher in psoriatic lesional tissue than nonlesional tissue. [5] [6] [7] Indeed, therapies that target either IL-17A or IL-17RA are similarly highly effective in reducing disease in patients with psoriasis. 1, [8] [9] [10] [11] Although these numerous lines of evidence implicate an important role for IL-17A, a nonredundant role for IL-17F has not been precluded.
Much of our current understanding of psoriasis pathophysiology and the effects of IL-17A blockade has largely been based on studies evaluating gene expression from skin biopsy specimens. 6, [12] [13] [14] Although these studies have provided significant insights into the pathways that might be involved in IL-17A-mediated pathogenesis, they are limited by the frequent incongruence between changes in mRNA and protein expression. Furthermore, they do not quantify the early microanatomically specific changes in protein expression, in particular large proteins, such as cytokines and chemokines. To date, protein expression response to therapy in psoriatic skin has been mostly demonstrated on a qualitative rather than quantitative level through the use of histology and immunohistochemistry (IHC). 12, [14] [15] [16] To increase our understanding of the inflammatory pathophysiology in psoriatic skin at a protein expression level and to identify a protein biomarker of IL-17A-mediated pathology, we conducted an exploratory study in 8 healthy subjects and 8 patients with psoriasis to quantify and compare the soluble proteomic profiles of lesional versus nonlesional skin before and after single-dose systemic treatment (300 mg administered subcutaneously) with secukinumab (a fully human anti-IL-17A mAb with a half-life of approximately 27 days) and/or healthy skin. Dermal open flow microperfusion, a novel technique that provides minimally invasive access to dermal interstitial fluid (dISF), was used to sample the dermis. [17] [18] [19] Dermal (dISF) samples were then analyzed for 170 proteins encompassing cytokines, chemokines, growth factors, cell adhesion molecules, and soluble receptors. Early proteomic changes that occur within the dermis after secukinumab treatment were complemented with gene expression changes extracted from full skin biopsy specimens. Our aim was to identify which pathways might be central to psoriasis pathology in skin and whether the antimicrobial peptide b-defensin 2 (BD-2) might be a protein biomarker of IL-17A-mediated pathology.
METHODS

Study design
This single-center clinical study was conducted according to ethical principles and good clinical practice at the Medizinische Universit€ at in Graz, Austria, after being approved by the ethics committee and Austrian health authority. Enrolled patients needed to sign informed consent forms and comply with the protocol requirements (ClinicalTrials.gov Identifier NCT01539213).
We enrolled 8 healthy subjects (mean age, 26.1 years) and 8 patients with psoriasis (mean age, 38.8 years). All 16 subjects were white, and all patients with psoriasis were male, as were 6 healthy subjects. All subjects received a single 300-mg subcutaneous injection of secukinumab on study day 1. Skin biopsy specimens (4-mm skin punch), serum samples, and dermal samples were obtained on study days 1 (before secukinumab treatment), 8 and 15 (7 and 14 days after secukinumab treatment). Details of the dermal sampling methodology were described previously. 19 In addition, baseline serum from patients with various inflammatory diseases sampled in multicenter trials conducted after ethics committee and health authority approval have been analyzed. Sera analyzed were from 289 patients with psoriasis (NCT01539213 and NCT00941031), 37 patients with PsA (NCT00809614), 56 patients with AS (NCT00809159), 68 patients with MS (NCT01051817), 94 patients with RA (NCT01426789), and 57 patients with Crohn disease (CD; NCT00584740).
Protein and RNA measurements
Free IL-17A and IL-17F levels in serum and dISF were quantified by using microparticle-based fluorescent sandwich immunoassays based on Erenna technology validated in human serum (Singulex IL-17A Human Immunoassay Kit, catalog no. 03-0017-05; Singulex IL-17F Human Immunoassay Kit, catalog no. 03-0018-03; Singulex, Alameda, Calif). The lower limit of quantification (LLOQ) for IL-17A was 0.64 pg/mL in dISF and 0.096 pg/ mL in serum, and that for IL-17F was 96.6 pg/mL in dISF and 14.4 pg/mL in serum. BD-2 was quantified by using ELISA (Alpha Diagnostic, catalog no. 100-250-BD-2). The LLOQ for BD-2 was 218 pg/mL in dISF and 32.5 pg/mL in serum. Sinistrin served as a reference substance and was used to estimate the absolute concentrations of biomarkers in dISF. 19 The chemiluminescent multiplex enzyme immunoassay platform from Aushon BioSystems (Billerica, Mass) was used to profile and quantify the levels of 170 proteins distributed over 43 panels. The panel of 170 proteins encompasses cytokines, cytokines receptor, chemokines, cell adhesion molecules, angiogenesis factors, matrix metalloproteinases (MMPs), growth factors, and neurotrophic factors (see Table E1 in this article's Online Repository at www.jacionline.org).
Total RNA was isolated from skin biopsy specimens by using the Qiagen RNeasy Micro Kit (Qiagen, Hilden, Germany). RNA isolated from commercial skin biopsy specimens (Asterand UK, Royston, United Kingdom) from healthy subjects (n 5 10) served as controls for gene expression data. Gene expression analysis was done by using quantitative RT-PCR (qRT-PCR) ) were seeded onto 96-well plates and incubated overnight. Thereafter, cells were incubated for another 20 hours in medium alone or 0.03 to 960 ng/mL IL-17A in the absence or presence of 1 ng/mL TNF-a, 0.03 to 960 ng/mL IL-17F in the absence or presence of 1 ng/mL TNF-a, or 0.03 to 960 ng/mL TNF-a. Supernatants were examined for the release of BD-2.
Statistical analysis
For the skin microperfusion study, log-transformed baseline (day 1) IL-17A and IL-17F protein levels were analyzed by using a mixed effects model with site (healthy volunteer or patient for serum levels and lesional or nonlesional psoriatic skin for skin levels) as a fixed effect and subject as a random effect, respectively. The adjusted geometric means (GMs) at each site were provided on the original scale together with the P values for comparisons between sites. Pearson correlation coefficients (denoted by r) between baseline protein levels (IL-17A and IL-17F) and efficacy scores (Psoriasis Area and Severity Index [PASI] score) were calculated together with the corresponding P values by site. Log-transformed baseline BD-2 levels in serum and skin were also analyzed by using a mixed effects model with site (healthy volunteer or patient for serum levels and healthy and lesional or nonlesional psoriatic skin for skin levels) and subject as a random effect, respectively. The adjusted GMs at each site were provided on the original scale together with the P values for comparisons between sites. IL-17F levels in serum from patients with psoriasis and BD-2 levels over time in serum and skin were log-transformed and analyzed by site by using a mixed effects model with visit day (baseline, day 8, and day 15) as a fixed effect and subject as a random effect, respectively. The adjusted GMs and 95% CIs at each visit were provided on the original scale together with P values for comparisons between visits. Pearson correlation coefficients between BD-2 levels and efficacy (PASI) scores were calculated together with the corresponding P values by site and visit. Any values less than the LLOQ (note: values less than the LLOQ differ for some samples because of a different sample dilution factor applied) were imputed by half the LLOQ.
In the secukinumab dose regimen study in patients with moderate-to-severe psoriasis (NCT00941031), serum samples were taken and analyzed for BD-2, IL-17A, and IL-17F. Correlations between PASI scores and BD-2, IL-17A, and IL-17F levels were investigated by using a Pearson correlation coefficient. BD-2, IL-17A, and IL-17F values were log-transformed before analysis. Values of less than the LLOQ were not included in the calculations.
Analyses were performed with PROC MIXED and PROC CORR in SAS software, version 9.4 (SAS Institute, Cary, NC).
RESULTS
Baseline IL-17A protein levels are increased in lesional versus nonlesional skin of patients with psoriasis
To understand the relative roles of IL-17A and IL-17F in psoriasis, we evaluated protein levels in the circulation (serum) and skin (dISF) of the 16 subjects in our study (NCT01539213).
Consistent with previous studies, baseline serum IL-17A protein levels were higher in patients with psoriasis than in healthy subjects (GM: 0.5 vs 0.2 pg/mL, respectively; P <.05). Posttreatment serum levels of free IL-17A could not be assessed because the IL-17A assay used measures not only free IL-17A but also IL-17A bound to secukinumab. No validated assay exists to measure free IL-17A in the presence of secukinumab. Serum IL-17F levels in patients with psoriasis (17.5 pg/mL) did not change significantly at day 15 from baseline after secukinumab (14.9 pg/mL, P 5 not significant). At baseline, serum IL-17A protein levels correlated well with PASI scores (r 5 0.93, P < .001; Fig 1, A) , whereas baseline IL-17F levels did not (r 5 0.01, P 5 .98; Fig 1, B) .
Dermal (dISF) levels of IL-17A protein at baseline were significantly higher in lesional than nonlesional psoriatic skin (GM: 9.8 vs 0.8 pg/mL, respectively; P < .01; Fig 1, C) . IL-17A was not detectable in the normal skin of healthy subjects (less than the LLOQ: <0.64 pg/mL). In contrast, baseline IL-17F levels in dISF were not significantly different between lesional and nonlesional skin, although IL-17F levels tended to be higher in lesional than nonlesional skin (GM: 317 vs 163 pg/mL, respectively; P 5 .105; Fig 1, C) . IL-17F protein levels were (Fig 1, A) and PASI scores versus IL-17F levels (Fig 1, B) . A linear regression fit is depicted by a red line, the strength of the linear relationship is indicated by using the Pearson correlation coefficient r, n indicates the number of values on each plot, and the P value shows the probability that the slope of the true relationship is zero. C, Baseline IL-17A and IL-17F levels in the dermis (dISF) of healthy volunteers (HV, circles) and lesional (L, squares) and nonlesional (NL, triangles) skin from patients with psoriasis. Red lines and values represent the adjusted GMs and are adjusted for relative recovery of the reference substance sinistrin (Dragatin et al 19 ). Data less than the LLOQ were imputed as half LLOQ and are shown as open symbols. **P < .01. NS, Not significant (P > .05); NT, not testable because of the number of samples less than the LLOQ in both groups.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 3 not measurable in the normal skin of healthy subjects (less than the LLOQ of 96.6 pg/mL; Fig 1, C) . Transcriptional analysis of IL-17 family members (IL-17A to IL-17F) in skin biopsy specimens confirmed these findings by demonstrating upregulation of mRNAs for IL-17A, IL-17F, IL-17C, and potentially IL-17E (IL-25) in psoriatic lesional skin compared with healthy skin, whereas expression of IL-17B was unchanged and that of IL-17D was reduced (see Fig E1 in this article's Online Repository at www.jacionline.org). Consistent with changes in protein levels, IL17A and IL17F mRNA levels were reduced after secukinumab treatment (see Fig E1) .
Proteomics screening of serum and dISF for IL-17A-responsive markers
To identify potential markers of IL-17A response proteins, we used a hypothesis-free proteomics screening approach measuring 170 proteins in dISF and serum before and after secukinumab treatment. By using a 1.5-fold change from baseline as a threshold, 89 proteins were shown to be dysregulated in dISF, serum, or both after treatment with secukinumab (Fig 2) . The 10 proteins showing the greatest fold decrease were antimicrobial peptides (BD-2 and lipocalin-2 [NGAL or LCN2]), MMPs (MMP-1 and MMP-8), IL-1 pathway members (IL-1b and IL-1ra), neutrophil proteins (myeloperoxidase), and neutrophilattracting (growth-regulated alpha protein [GRO-a] or CXCL1 and epithelial cell-derived neutrophil-activating peptide 78 [ENA-78] or CXCL5) or T H 17 cell-attracting (macrophage inflammatory protein 3a or CCL20) chemokines (Table I) . Levels of other chemokines, including GRO-g/CXCL3 and I-309/CCL1, were also decreased after secukinumab. We could not detect a change in TNF-a levels. The 5 proteins showing the greatest fold increase were T H 2 cell-associated proteins (IgE and eotaxin-2/CCL24), adiponectin (Acrp-30), leptin, and endoglin. An early downregulation of the antimicrobial peptides BD-2 (encoded by the gene DEFB4A), BD-3 (DEFB103B), lipocalin-2 (LCN2), LL-37 (CAMP), S100A8, and S100A9, as well as neutrophil-and T H 17-attracting chemokines (CXCL1, IL-8/ CXCL8, and CCL20, respectively) and the IL-1 family members IL-36a (IL36A), IL-36b (IL36B), IL-36g (IL36G), and IL-36RN (IL36RN), was also observed on the mRNA level (see Figs E2-E4 in this article's Online Repository at www.jacionline.org), thereby confirming and extending observations made on the protein level. BD-2 (also known as skin antimicrobial peptide 1) was the protein showing the highest fold change in both dermis and serum and was selected for further study.
BD-2 levels correlate with IL-17A and psoriasis clinical severity and decrease after IL-17A blockade BD-2 levels were further and more specifically quantified by using ELISA in skin (dISF) and serum before and after secukinumab treatment (Fig 3) . At baseline, serum levels of BD-2 protein were significantly higher in patients with psoriasis than in healthy subjects (GM: 5746 vs 82 pg/mL, respectively; P <.001; Fig 3) . Serum BD-2 levels decreased rapidly in patients with psoriasis after a single 300-mg subcutaneous dose of secukinumab (GM: 971 pg/mL at day 8 and 649 pg/mL at day 15; P < .0001 vs baseline for both time points). Dermal (dISF) BD-2 levels were also significantly higher in lesional skin than in nonlesional psoriatic skin at baseline (GM: 2747 vs 417 pg/mL, respectively, P <.001; Fig 3) . In contrast, dermal BD-2 levels in healthy subjects were all less than the LLOQ (P <.001 vs lesional skin in patients with psoriasis, Fig 3) . After secukinumab treatment, mean BD-2 levels in lesional skin decreased by 80% at day 8 and approached levels close to the LLOQ at day 15 after treatment with secukinumab (GM: 550 pg/mL at day 8 [P < .05] and 196 pg/mL at day 15 [P < .01], Fig 3) . Thus BD-2 in both serum and dISF is responsive to IL-17A inhibition.
To confirm that IL-17A mediates BD-2 expression in the skin, we tested cytokine-stimulated BD-2 expression in epidermal keratinocytes, dermal fibroblasts, and dermal microvascular endothelial cells. Of the 3 cell types, only epidermal keratinocytes produced BD-2 (Fig 4) . Although IL-17A, IL-17F, and TNF-a all induced low levels of BD-2 at high concentrations, the combination of IL-17A and TNF-a was synergistic and induced high levels of BD-2 expression. Thus epidermal BD-2 protein levels are increased in patients with psoriasis and rapidly decrease in dermis and serum after secukinumab treatment. Upper panel, left, Baseline human BD-2 levels in the serum of healthy volunteers (HV) and patients with psoriasis (Pso). Upper panel, right, Serum BD-2 levels after a single dose of 300 mg of secukinumab administered subcutaneously (GM 6 95% CI). Lower panel, left, Baseline BD-2 levels in the dermis (dISF) of lesional (Pso L) and nonlesional (Pso NL) skin from patients with psoriasis and skin from healthy subjects (HV). Lower panel, right, Dermal BD-2 levels after a single dose of 300 mg of secukinumab administered subcutaneously (GM 6 95% CI). Red horizontal bars depicts the GM concentration. All data less than the LLOQ (218 pg/mL for healthy volunteers and 109 pg/mL for patients with psoriasis) were imputed as half LLOQ and are shown as open symbols. **P < .01 and ***P < .001.
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To determine whether BD-2 could be a marker of psoriasis disease activity, we compared BD-2 serum levels with PASI scores. The clinical efficacy of secukinumab has been previously documented, and similarly in this study, the mean PASI score decreased by 62.5% at day 22 after a single dose of 300 mg of secukinumab administered subcutaneously (P < .0001 vs baseline). BD-2 levels also decreased in correlation with reductions in clinical disease severity (PASI scores at baseline, day 8, and day 15; r 5 0.87-0.89; P < .01). These data were confirmed by analyzing stored baseline serum samples from a second, larger phase 2b study in patients with psoriasis (NCT00941031). 20 In this validation cohort there was a significant correlation between serum BD-2 and IL-17A levels (n 5 199; r 5 0.70, P < .001, Fig 5) , as well as serum BD-2 levels and PASI disease activity (n 5 281, r 5 0.53, P < .001; Fig 5) . Thus serum BD-2 levels correlate with both serum IL-17A levels and psoriasis disease activity. Furthermore and in line with the close correlation of serum levels of BD-2 with IL-17A, serum levels of IL-17A show a significant correlation with psoriasis disease activity (n 5 206, r 5 0.44, P < .001; Fig 5) . Little correlation was observed for IL-17F with either psoriasis disease activity (n 5 177, r 5 0.15, P < .05; Fig 5) or serum BD-2 levels (n 5 173, r 5 0.15, P < .05; Fig 5) .
Because IL-17A levels are increased and IL-17A is a pathogenic driver in multiple autoimmune diseases, we sought to determine whether BD-2 could be a marker of IL-17A activity in patients with diseases other than psoriasis. We analyzed BD-2 levels in stored baseline serum (n 5 601) from previous clinical studies in several autoimmune diseases. BD-2 levels were highly increased in the sera of patients with diseases having skin involvement, such as psoriasis and PsA, and only at moderate levels in those with diseases with minimal to no skin involvement, such as AS, RA, MS, and CD (Fig 6) . Although previous or current psoriatic inflammation of the skin is required for the diagnosis of PsA, many patients with PsA do not have detectable skin lesions at the time of evaluation. Thus we evaluated whether BD-2 levels were different in subjects with or without ongoing skin involvement and found that BD-2 levels were higher in those patients with active skin involvement compared with those who did not (GM: 1493 vs 454 pg/mL, P < .01). We also assessed IL-17A and IL-17F levels in patients with psoriasis, PsA, and AS and found that they were expressed at similar levels in PsA patients with or without skin involvement (Fig 6) . Thus BD-2 appears to be a biomarker of IL-17A pathogenesis in the skin.
DISCUSSION
In this study our aims were to (1) better understand the role of IL-17A in psoriasis pathogenesis by defining the early effects of IL-17A blockade on inflammatory proteins in both serum and the dermis and (2) identify soluble biomarkers of IL-17A pathway activation. Previous studies quantifying skin gene expression by using transcriptomics or qualitatively assessing protein expression by means of IHC before and after anti-IL-17A therapy have provided important information, 12, 13 but the conclusions are limited by the often discrepant timing and levels of gene and protein expression. This might be of particular relevance because proteins are the final effector molecules in biological systems and significant differences to their corresponding mRNA levels can exist. 21 To quantify soluble skin proteins involved in psoriasis pathogenesis, we used dermal open flow microperfusion. 18 As predicted based on IHC and mRNA transcription data, we found high IL-17A protein levels in lesional skin from patients with psoriasis. Similarly and consistent with previous 12, 13 and our own mRNA transcription data, we could not detect either IL-17A or IL-17F protein in skin of healthy volunteers. Interestingly, we found detectable but lower IL-17A protein levels in nonlesional skin of patients with psoriasis (2/8 tested), suggesting that nonlesional skin is not normal and has a low level of ongoing IL-17A pathway activation. In the serum we confirmed previous data, now using a highly sensitive and validated assay, that IL-17A levels in our small study of 8 subjects are increased in patients with psoriasis and correlate with disease activity. Although IL-17F protein levels in patients with psoriasis were much higher than IL-17A levels, they were not consistently upregulated in lesional versus nonlesional skin in all psoriasis plaques and did not In each plot the red line is from a linear regression fit, the strength of the linear relationship is indicated by using the Pearson correlation coefficient r, and n indicates the number of values on each plot. The P value is from a test that the slope of each linear regression line equal zero; the smaller the P value, the less likely it is that the slope of the true relationship equals zero.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 3 correlate with psoriasis disease activity as measured by using PASI scores. One possible explanation for this discrepancy is that IL-17A is about 100-fold more potent than IL-17F for signaling through IL-17R, 22 a feature also seen for BD-2 induction in keratinocytes in Fig 4. We sought to validate this finding using a larger independent cohort of patients with psoriasis. In the validation set serum IL-17A levels continued to have a good correlation, whereas IL-17F levels had a weaker if not poor correlation with PASI scores. Combined with the excellent and similar efficacy of compounds that target IL-17RA (which blocks IL-17A, IL-17C, IL-17E, and IL-17F) and IL-17A only (reviewed in Patel and Kuchroo 1 ), we conclude that IL-17A has a more dominant role in driving pathologic changes in psoriatic skin than IL-17F.
To identify in vivo IL-17A-responsive proteins, we treated patients with psoriasis with a single dose of secukinumab, a selective anti-IL-17A antibody with previously demonstrated 11, 12, 23 pharmacology and clinical efficacy in patients with psoriasis. Secukinumab has been shown in the patients evaluated in this study to reach pharmacologically active skin concentrations at the time of sampling. 19 Proteomics analysis after selective blockade with secukinumab showed that most changes occurred in the dermis. Many of the most strongly downmodulated proteins mapped to the canonical IL-17A pathway (MetaCore from Thomson Reuters) and were linked to keratinocyte activation, inflammation, and neutrophil and leukocyte/dendritic cell recruitment. 24 Three of the 10 top downregulated proteins (myeloperoxidase, CXCL1, and CXCL5) were neutrophil associated, verifying previously described effects of anti-IL-17A therapy on this hallmark feature of psoriasis 25 and the established role of IL-17A in inducing neutrophil recruitment. As previously seen with transcriptional analysis, the protein expression of IL1b, MMP-1, and MMP-8 in skin decreased after IL-17A blockade. However, the changes were limited to the skin and not seen in serum, likely because of the restricted local production and action of IL-1b and MMPs. Similarly, the chemokines CXCL1, CXCL3, CXCL5, CCL1, and CCL20 were also decreased in the skin but not serum after secukinumab, destroying the chemokine gradient from serum into skin. Although TNF-a mRNA expression is decreased after secukinumab, 12 we did not detect changes in protein levels in this study. The 2 proteins with levels that increased most in dISF were IgE and CCL24, suggesting a skewing of the skin immune response from T H 17 to T H 2. Interestingly, mRNA for IL-17E (IL-25), which promotes T H 2, was also slightly increased in skin after secukinumab therapy. Thus IL-17A blockade leads to decreases in skin proinflammatory cytokines, decreased destruction of the connective tissues, skewing of the immune response away from T H 17, and decreased recruitment of leukocytes, particularly neutrophils, into the skin. BD-2 was the protein with by far the biggest change in the dermis and serum after anti-IL-17A treatment (Fig 2 and Table I ). This confirms on a protein level the finding that levels of DEFB4A mRNA encoding BD-2 protein are decreased after IL-17A blockade.
12,13 DEFB4A mRNA is highly induced by IL-17A in epidermal keratinocytes and reconstituted human epidermis, 13, [26] [27] [28] and BD-2 protein is primarily located in the epidermal layer of the skin, 29, 30 where it is a potent antimicrobial peptide. 31 In addition, BD-2 is chemotactic for cells that express CCR2, 32 CCR6, 33 or both, such as neutrophils, 32, 34 monocytes/ macrophages, 32 immature dendritic cells, and T cells, 35 and is involved in arrest of T H 17 cells on inflamed endothelium. 27 Our study confirms BD-2 is expressed in skin by epidermal keratinocytes, and recent results show that its expression is highly induced by IL-17A in a synergistic manner with TNF-a. 36 Thus BD-2 is an IL-17A-responsive innate inflammatory protein produced in the skin by epidermal keratinocytes.
With the above information, we sought to define whether BD-2 could be validated as a biomarker of IL-17A-mediated skin pathology in patients with psoriasis. We also recognized that a serum biomarker would be more useful than one that would require a skin biopsy or microperfusion. Previously, Jansen et al 29 showed that serum BD-2 levels correlated with psoriasis disease severity, as defined by PASI score. We have confirmed this finding with a larger cohort of patients with psoriasis and have extended it by showing that serum BD-2 levels correlate even more strongly with IL-17A. Importantly, neutralizing IL-17A with secukinumab decreased BD-2 levels not only in skin but also in serum, and this reduction occurred within 1 week, the earliest time point that we measured. Given the dramatic reduction seen at 1 week after secukinumab treatment, it is likely that BD-2 responds even earlier.
Lastly, we tested BD-2 levels in baseline serum samples from patients with diseases thought to be IL-17A driven and showed that BD-2 levels were most highly increased in patients with psoriatic skin inflammation.
However, there are caveats and limitations of this study. First, many of the mechanistic findings in the dermis were made in a relatively small number of subjects. However, we could confirm a link between the dermis and serum in our cohort and then reproduce many findings in serum from a larger cohort. Larger studies with skin microdialysis would be needed to confirm the dermal rather than serum data. By using IHC, other candidates for soluble biomarkers of IL-17A activity in patients with psoriasis have emerged, including S100A7 and S100A8, 13 but these proteins were not evaluated here. BD-2 might also respond to mediators other than IL-17A, and our study shows that IL-17A acts in synergy with TNF-a to induce BD-2 by skin epithelium. There are conflicting data regarding the effect of TNF-a blockade or other effective psoriasis treatments on BD-2 levels. In one study DEFB4A mRNA levels in skin biopsy specimens did not change after etanercept, whereas they did decrease dramatically with IL-17A blockade. 13 In another study BD-2 protein staining was qualitatively decreased by IHC after etanercept. 15 There was no decrease, and possibly an increase, in serum BD-2 levels after treatment with fumaric acid esters. 37 Increased serum BD-2 levels have been linked to atopic dermatitis and systemic lupus erythematosus, [38] [39] [40] and BD-2 can be expressed by other epithelia than skin, including lung and gastrointestinal epithelia. 41, 42 Although we did not detect high BD-2 levels in patients with gut inflammation (CD), we have not tested lung diseases. BD-2 is not an exclusive biomarker for IL-17A-mediated skin pathology in psoriasis. However, all studies (including the current one) testing the association of serum or skin BD-2 protein levels and/or skin DEFB4A mRNA expression with psoriasis disease activity, serum IL-17A levels, or response to IL-17A blockade are consistent and robust.
In summary, our study shows that IL-17A is a dominant driver of skin pathology in patients with psoriasis, and serum BD-2 is an easily measurable biomarker of psoriasis disease activity that responds rapidly and robustly to IL-17A inhibition by secukinumab. Serum BD-2 levels might be a surrogate for IL-17A activity and could be used to monitor responses to IL-17A-targeted therapies.
METHODS
Gene expression analysis
Total RNA extraction. Four-millimeter punch skin biopsy tissue samples were collected and immersed in 1.5 mL of RNAlater RNA Stabilization Reagent. Total RNA was isolated from tissue samples by using the Qiagen RNeasy Micro Kit and eluted in 12 mL of RNase-free water. RNA isolated from commercial skin biopsy specimens (Asterand UK) from healthy subjects (n 5 10) served as controls for gene expression data. Twenty to 50 ng of RNA was preamplified by using the Affymetrix SensationPlus FFPE Amplification kit (Affymetrix, Santa Clara, Calif).
FIG E1.
Expression of IL-17 family member genes in skin biopsy specimens from patients with psoriasis and healthy subjects before and after treatment with secukinumab. qRT-PCR was performed on skin biopsy specimens from lesional skin of patients with psoriasis enrolled in the study (n 5 6; data from 2 subjects are not shown because of missing data at either baseline or day 8). Healthy control skin biopsy specimens (n 5 10) were obtained from a commercial source (Asterand). Y-axes show normalized RQs. Red lines depict median values. *P < .05, **P < .01. NS, Not significant (P > .05). BL, Baseline; HV, healthy volunteers.
FIG E2.
Early transcriptional downregulation of b-defensins and antimicrobial peptides. mRNA gene expression from lesional skin biopsy specimens and healthy subjects were all determined by using NanoString technology. Healthy control skin biopsy specimens (n 5 10) were obtained from a commercial source (Asterand). Y-axes show normalized RQs. Red lines depict median values. *P < .05, **P < .01. NS, Not significant (P > .05). BL, Baseline; HV, healthy volunteers.
FIG E3
. mRNA expression analysis indicates early effects on T H 17-and neutrophil-attracting chemokines. mRNA gene expression from lesional skin biopsy specimens and healthy subjects were all determined by using NanoString technology. Healthy control skin biopsy specimens (n 5 10) were obtained from a commercial source (Asterand). Y-axes show normalized RQs. Red lines depict median values. *P < .05. NS, Not significant (P > .05). BL, Baseline; HV, healthy volunteers.
FIG E4
. mRNA expression analysis indicates early effects of IL-17A blockade on the IL-1 family cytokines IL36a, IL-36b, and IL-36g. mRNA gene expression from lesional skin biopsy specimens and healthy subjects was determined by using NanoString technology. Healthy control skin biopsy specimens (n 5 10) were obtained from a commercial source (Asterand). Y-axes show normalized RQs. Red lines depict median values. *P < .05, **P < .01. NS, Not significant (P > .05). BL, Baseline; HV, healthy volunteers. 
